Table 1.
Characteristics of the included studies in this meta-analysis.
| First author | Kim | Cabel | Yang | Leal | Suzuki | Fedyanin | Huffman | Yuan |
|---|---|---|---|---|---|---|---|---|
| Publication (yr) | 2019 | 2019 | 2020 | 2020 | 2020 | 2020 | 2022 | 2022 |
| Country | Korea | France | China | USA | Japan | Russia | USA | China |
| Patients (n) | 19 | 19 | 46 | 50 | 46 | 42 | 88 | 100 |
| Mean age (range/IQR) | 60 (41–77) | 62 (45–78) | 54 (28–78) | 60 (30–77) | 72 (46–92) | NA | NA | NA |
| Male (%) | 88 | 84 | 83 | 72 | 76 | NA | NA | NA |
| Serum samples (n) | 107 | 50 | 296 | 120 | 40 | NA | 271 | NA |
| Sample type | Plasma | Plasma | Plasma | Plasma | Plasma | Plasma | Plasma | Plasma |
| Tissue testing methods | WGS | NGS | NGS | NA | NA | NGS | WES | NGS |
| ctDNA testing methods | PCR | ddPCR | NGS | NGS | ddPCR | ddPCR | NGS | NA |
| Tissue tumor oncogenes (n) | NA | 39 | 1021 | NA | NA | 50 | NA | 425 |
| ctDNA oncogenes (n) | NA | 5 | 50 | 58 | 52 | NA | NA | NA |
| Post-operative ctDNA testing time | < 12 mo | <1 mo | 9–48 d | 6.5 wk | 7.3 d | 7 d | 16 wk | 4 d |
| The time ahead for clinical detection | 4.05 mo | NA | 6 mo | 8.9 mo | 6 mo | NA | NA | NA |
| Centers (n) | Multicentre | Single center | Single center | Multicentre | Multicentre | NA | Multicentre | NA |
| Study design | Retrospectively | Prospectively | Prospectively | Retrospectively | Prospectively | Prospectively | Retrospectively | Prospectively |
| Clinicalstage | II-IV | NA | I-III | IA-IV | II-III | I-IV | I-III | II-III |
| TNM staging | T3-T4b/N0-N3b/M0 | T1-T4/N0-N+ | pT1a-pT4a/pN0-pN3b/pM0 | ypT0-ypT4b/ypN0-ypN3b/ypM0-ypM1 | NA | NA | NA | NA |
| Median follow-up (range/IQR, mo) | 12 | 26 (11–35) | 29.1 (5.7–32.3) | 42 | 12.2 | NA | 34.8 | NA |
dd PCR = droplet digital polymerase chain reaction, IQR = interquartile range, n = number, NA = not available, NGS = next-generation sequencing, PCR = polymerase chain reaction, WES = whole-exome sequencing, WGS = whole-genome sequencing.